Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension

BMC Pulmonary Medicine
Asuka FurukawaAkio Kawamura

Abstract

In this report, we describe the first successful case of transition from subcutaneous administration of treprostinil to selexipag in a patient with severe pulmonary arterial hypertension (PAH), by evaluating hemodynamic changes and exercise tolerance. A 38-year-old female with idiopathic PAH (IPAH) had received initial triple combination therapy (macitentan PO, tadalafil PO, and treprostinil SC) and achieved excellent improvement in hemodynamics. Afterwards, due to the development of side effects from subcutaneous administration, we replaced treprostinil therapy with oral selexipag, resulting in stable hemodynamic parameters and exercise capacities. We report the first case of successful replacement of treprostinil (20.1 ng/kg/min) with selexipag (1600 μg BID) as a component of triple combination therapy, which provides incentive to perform a larger, prospective exchange study.

Citations

Oct 12, 2018·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Sherif M Fanous, Munir Janmohamed
Jul 6, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·John J RadosevichJeremy Feldman
Oct 2, 2020·Pediatric Pulmonology·Charissa W Kam, Fadel E Ruiz
Jan 15, 2020·Journal of Cardiovascular Pharmacology·Kishan S ParikhSudarshan Rajagopal
Jan 15, 2021·European Heart Journal. Case Reports·Sarah BlissettVaikom S Mahadevan
Jul 10, 2021·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Elizabeth ColglazierJeffrey R Fineman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The New England Journal of Medicine
Alejandro MacchiaGianni Tognoni
The New England Journal of Medicine
Adriano R Tonelli, Raed A Dweik
The New England Journal of Medicine
Timothy S AndersonWalid F Gellad
© 2022 Meta ULC. All rights reserved